Cryoport (CYRX) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 13.5% YoY to $50.2M, while adjusted EBITDA from continuing operations was $1.1M versus a $0.6M loss a year earlier.

• Supported 23 commercial therapies and a record 788 clinical trials, including 99 Phase III trials; FY2026 revenue guidance increased to $197M–$199M.

Financial highlights

• Q3 revenue was $50.2M versus $44.2M; 9M revenue increased 12.4% YoY to $147.0M.

• Q3 loss from continuing operations was $10.9M versus $6.7M; net loss attributable to common stockholders was $12.9M, or $0.25 per share.

• 9M loss from continuing operations was $28.5M versus $25.4M; 9M net loss was $29.7M versus net income of $89.9M in 2025, which included the CRYOPDP divestiture gain.

• Q3 gross profit increased 11.8% YoY to $23.8M.

Outlook and guidance

• FY2026 revenue guidance rose to $197M–$199M from $192M–$196M, representing 12% organic growth at the midpoint.

• Q4 guidance assumes continuation of year-to-date growth among current clients and excludes revenue from potential new therapy approvals, which may take time to ramp.

• Five additional BLA/MAA filings, two potential therapy approvals and one supplemental geographic expansion approval were expected in the remainder of 2026; four anticipated filings shifted to 2027.

• Management expects further EBITDA margin expansion in 2027 and beyond as BioServices capabilities come online and utilization increases.